Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

Original languageEnglish
Pages (from-to)1341-1344
Number of pages4
JournalTransplantation
Volume83
Issue number10
DOIs
Publication statusPublished - May 2007

Fingerprint

Hepatitis Delta Virus
Lamivudine
Chronic Hepatitis B
Coinfection
Hepatitis B virus
Chronic Hepatitis
Liver Transplantation
Immunoglobulins
Appointments and Schedules
Recurrence
Survival

Keywords

  • Hepatitis B virus
  • Hepatitis delta virus
  • Lamivudine
  • Liver transplantation
  • Outcome

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

@article{e948b568ca664d86b3ffe25a753919c4,
title = "Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection",
abstract = "BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P",
keywords = "Hepatitis B virus, Hepatitis delta virus, Lamivudine, Liver transplantation, Outcome",
author = "Lucio Caccamo and Francesca Agnelli and Paolo Reggiani and Umberto Maggi and Donato, {M. Francesca} and Stefano Gatti and Giovanni Paone and Ernesto Melada and Giorgio Rossi",
year = "2007",
month = "5",
doi = "10.1097/01.tp.0000264001.69308.be",
language = "English",
volume = "83",
pages = "1341--1344",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection

AU - Caccamo, Lucio

AU - Agnelli, Francesca

AU - Reggiani, Paolo

AU - Maggi, Umberto

AU - Donato, M. Francesca

AU - Gatti, Stefano

AU - Paone, Giovanni

AU - Melada, Ernesto

AU - Rossi, Giorgio

PY - 2007/5

Y1 - 2007/5

N2 - BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

AB - BACKGROUND. Posttransplant combined lamivudine (LAM) and immunoglobulin (HBIg) prophylaxis is the gold standard in the case of single hepatitis B virus (HBV), but is still not recommended in the case of patients coinfected with hepatitis delta virus (HDV). METHODS. We compared two consecutive groups of chronic HDV carriers who survived >6 months after liver transplantation of the risk of recurrence, survival and HBIg requirements: 21 received passive prophylaxis (HBIg group) and 25 were treated with combined prophylaxis (LAM+HBIg group). The immunoprophylaxis schedule was the same in both groups: intramuscular HBIg targeted to maintain anti-HBs levels of >500 IU/L during the first 6 posttransplant months and >200 IU/L thereafter. RESULTS. The mean length of follow-up in the two groups was significantly different (133 vs. 40 months; P

KW - Hepatitis B virus

KW - Hepatitis delta virus

KW - Lamivudine

KW - Liver transplantation

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=34249062310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249062310&partnerID=8YFLogxK

U2 - 10.1097/01.tp.0000264001.69308.be

DO - 10.1097/01.tp.0000264001.69308.be

M3 - Article

VL - 83

SP - 1341

EP - 1344

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -